GlassScriptPhysician profile
Yolanda C Brady
NPI 1982640736
$2,101.11
in general payments reported to CMS, 2019-2025
22 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2021: $251 · 2022: $247 · 2023: $632 · 2024: $373 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $623.87 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $440.07 | 2022-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $166.02 | 2022-2025 | Veozah |
| Horizon Therapeutics Plc | $139.86 | 2023 | Krystexxa |
| Exact Sciences Corporation | $108.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $93.16 | 2019 | |
| Amgen INC. | $83.27 | 2022-2025 | Evenity |
| Abbvie INC. | $70.78 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $67.93 | 2025 | Gemtesa |
| Glaxosmithkline, LLC. | $44.89 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $41.18 | 2021 | |
| Amarin Pharma, INC. | $33.32 | 2021-2022 | |
| Insulet Corporation | $22.96 | 2023 | Omnipod |
| Shield Therapeutics INC | $22.47 | 2025 | |
| Collegium Pharmaceutical, INC. | $20.55 | 2025 | Jornay Pm |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.22 | 2024 | Freestyle Libre |
| Dynavax Technologies Corporation | $19.72 | 2022 | |
| Ethicon US, LLC | $19.25 | 2019 | |
| Ironshore Pharmaceuticals INC. | $16.49 | 2023 | Jornay Pm |
| Dexcom, INC. | $16.41 | 2023 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $15.35 | 2021 | |
| Pfizer INC. | $14.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yolanda Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.